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Abstract	There	is	a	perfusion	deficit	in	Alzheimer's	disease	(AD),	commencing	in	the	precuneus	and	spreading	to	other	parts	of	the	cerebral	cortex.	The	deficit	anticipates	the	development	of	dementia,	contributes	to	brain	damage,	and	is	caused	by	both	functional	and	structural	abnormalities	of	the	cerebral	vasculature.	Most	of	the	abnormalities	are	probably	secondary	to	the	accumulation	of	Aβ	but	the	consequent	hypoperfusion	may,	in	turn,	increase	Aβ	production.	In	the	early	stages	of	disease,	abnormalities	that	cause	vasoconstriction	predominate.	These	include	cholinergic	vascular	denervation,	inhibition	of	endothelial	nitric	oxide	synthase,	increased	production	of	endothelin-1	production	and	possibly	also	of	angiotensin	II.	Patients	with	AD	also	have	an	increased	prevalence	of	structural	disease	of	cerebral	microvessels,	particularly	CAA	and	capillary	damage,	and	particularly	in	the	later	stages	of	disease	these	are	likely	to	make	an	important	contribution	to	the	cerebral	hypoperfusion.	The	metabolic	abnormalities	that	cause	early	vascular	dysfunction	offer	several	targets	for	therapeutic	intervention.	However,	for	intervention	to	be	effective	it	probably	needs	to	be	early.	Prolonged	cerebral	hypoperfusion	may	induce	compensatory	circulatory	changes	that	are	themselves	damaging,	including	hypertension	and	small	vessel	disease.	This	has	implications	for	the	use	of	antihypertensive	drugs	once	there	is	accumulation	of	Aβ	within	the	brain.		
Introduction	A	major	contributor	to	the	energy	deficit	in	Alzheimer’s	disease	(AD)	is	the	reduction	in	cerebral	perfusion	that	results	from	dysfunction	and	structural	
abnormalities	of	the	cerebral	vasculature.	As	discussed	elsewhere	in	this	mini-symposium,	there	are	also	other	contributors	to	the	energy	deficit	in	Alzheimer’s	disease	(AD),	including	extracranial	abnormalities	that	affect	cerebral	blood	supply	and	intracellular	disturbances	of	mitochondrial	function,	but	those	are	not	covered	in	the	present	review.	Within	this	review,	we	consider	three	questions:	1. Is	cerebral	hypoperfusion	in	AD	caused	by	reduced	demand	or	reduced	supply?	2. What	are	the	mechanisms	of	the	hypoperfusion?	3. What	are	the	therapeutic	implications?		
Reduced	demand	or	reduced	supply?	The	relative	contributions	of	falling	metabolic	demand	and	reduction	in	blood	supply	vary	according	to	the	stage	of	disease.	In	preclinical	and	early	AD	there	is	evidence	from	multiple	studies	employing	a	range	of	methods	that	the	cerebral	hypoperfusion	is	pathological	rather	than	physiological,	i.e.	the	decline	in	perfusion	exceeds	the	reduction	in	metabolic	demand,	and	causes	tissue	damage.	Metabolic	demand	may,	in	fact,	be	increased	during	the	earliest	stages	of	amyloid	accumulation	(11,	27).	Some	of	the	data	comes	from	imaging	studies	using	arterial	spin-labeled	perfusion	magnetic	resonance	imaging	(ASL-MRI)	or	2-deoxy-2-(18F)fluoro-D-glucose	positron	emission	tomography	(FDG-PET)	(there	is	a	near-perfect	topographical	correspondence	between	changes	in	ASL-MRI	and	FDG-PET	in	AD	−	see,	for	example	(24)).	In	people	with	mutations	that	cause	autosomal	dominant	forms	of	AD,	in	whom	the	timing	of	onset	of	the	AD	is	highly	
predictable,	a	reduction	in	glucose	uptake	is	demonstrable	by	FDG-PET	at	least	10	years	before	the	onset	of	clinical	disease	and	before	there	is	detectable	atrophy	(11).	The	decline	shows	a	consistent	pattern	of	topographical	progression,	starting	in	the	precuneus	(medial	parietal	cortex)	and	extending	along	the	cingulate	gyrus,	lateral	part	of	the	parietal	lobe	and	anterior	part	of	the	occipital	lobe,	then	into	the	rest	of	the	cerebrum.	A	similar	pattern	of	progression	of	hypoperfusion	was	demonstrated	by	ASL-MRI	in	sporadic	AD	(12).	In	patients	with	MCI	the	hypoperfusion	was	most	pronounced	in	the	precuneus	and	posterior	cingulate	cortex	but	also	involved	lateral	parietal,	occipital	and	frontal	cortex.	Perfusion	declined	significantly	in	the	temporal	cortex	only	when	patients	became	demented	and	did	not	fall	in	the	hippocampus.	Similar	findings	were	reported	in	earlier	studies	on	people	with	MCI	(5,	30)	and	in	healthy	carriers	of	the	APOE	ϵ4	allele	(65),	a	strong	genetic	risk	factor	for	AD.	This	stereotypical	distribution	of	hypoperfusion	does	not	bear	an	obvious	relationship	to	the	distribution	of	cerebral	atrophy,	which	correlates	with	that	of	neurofibrillary	tangle	pathology,	commencing	in	the	inferomedial	part	of	the	temporal	lobes	before	spreading	to	other	parts	of	the	cerebrum	(11).	The	distribution	of	hypoperfusion/reduced	glucose	uptake	correlates	much	more	closely	with	that	of	the	preceding	accumulation	of	amyloid	(see	for	example	(11,	27)).	We	recently	used	a	biochemical	approach	to	assess	the	adequacy	of	perfusion	and	oxygenation	of	the	precuneus	in	early	AD.	We	compared	the	levels	of	two	myelin	proteins,	myelin-associated	glycoprotein	(MAG),	which	is	highly	susceptible	to	reduced	tissue	oxygenation,	and	proteolipid	protein-1	(PLP1),	which	is	relatively	resistant	(8,	9).	Both	myelin	proteins	are	synthesized	in	the	
oligodendrocyte	cell	body	and	require	energy-dependent	transport	to	reach	their	sites	of	insertion	into	the	myelin	sheath	(Figure	1).	PLP1	is	distributed	throughout	the	myelin	sheath	whereas	MAG	is	inserted	only	far	from	the	cell	body,	in	the	adaxonal	loop	of	myelin,	the	first	part	of	the	sheath	to	degenerate	when	blood	supply	is	insufficient	to	meet	the	energy	demands	of	the	oligodendrocyte.	Both	myelin	proteins	are	very	stable	under	post-mortem	conditions	(9),	and	as	they	have	half-lives	of	several	months	(47,	136),	a	decline	in	the	MAG:PLP1	ratio	in	post-mortem	brain	tissue	reflects	a	pathological	reduction	in	ante-mortem	perfusion	over	a	relatively	long	period	prior	to	death.	We	showed	that	the	MAG:PLP1	ratio,	was	reduced	in	the	precuneus	by	~50%	in	Braak	stage	III-IV	disease	(75),	indicating	that	even	in	early	AD	there	is	a	disparity	between	oligodendrocyte	energy	demand	and	supply	in	the	first	region	of	brain	to	show	hypoperfusion.	Tarumi	et	al	(131)	used	near-infrared	spectroscopy	to	compare	the	tissue	oxygenation	index	(a	measure	of	the	saturation	of	haemoglobin	by	oxygen)	in	frontal	cortex	of	people	with	amnestic	MCI	and	age-matched	controls.	In	amnestic	MCI	patients	the	tissue	oxygenation	index	was	significantly	reduced,	both	at	rest	and	after	a	sit-stand	manoeuvre,	indicating	increased	oxygen	extraction.	Had	hypoperfusion	been	a	response	to	reduced	metabolic	demand	rather	than	a	pathological	reduction	in	blood	supply,	the	tissue	oxygenation	index	would	have	been	higher	rather	than	lower.	Cerebral	hypoperfusion	predicts	the	development	of	dementia	in	patients	with	MCI	and	the	rate	of	cognitive	decline	in	patients	with	AD	(14,	16,	22).	The	fact	that	the	hypoperfusion	actually	damages	the	brain,	even	in	preclinical	or	early	disease,	is	well	demonstrated	on	imaging	of	cerebral	white	matter	in	
people	with	mutations	that	cause	autosomal	dominant	forms	of	AD.	A	recent	study	showed	that	people	with	such	mutations	had	a	greater	volume	of	white	matter	hyperintensities	(WMH)	several	years	before	clinical	disease,	indicating	that	the	hypoperfusion	was	severe	enough	to	cause	tissue	damage	(67).	The	increase	in	WMH	was	most	pronounced	in	the	parietal	and	occipital	lobes;	as	noted	above,	this	corresponds	approximately	to	the	distribution	of	early	amyloid	accumulation	and	reduced	perfusion	in	the	overlying	cerebral	cortex.	The	relationship	between	cortical	amyloid	and	WMH	is	likely	to	be	relevant	to	the	pathogenesis	of	the	white	matter	hypoperfusion	(see	below).	Other	evidence	for	a	relationship	between	amyloid	burden	and	WMH	comes	from	an	MRI	study	of	150	cognitively	normal	people	by	Scott	et	al	(122).	The	authors	found	that	amyloid	burden,	as	assessed	by	measuring	Aβ42	level	in	the	CSF,	was	an	independent	predictor	of	total	WMH	volume.	Lee	and	colleagues	(67)	found	some	correlation	between	WMH	and	the	presence	of	microbleeds,	suggesting	a	contribution	from	cerebral	amyloid	angiopathy.	However,	the	increase	in	WMH	remained	significant	after	controlling	for	presence	of	microbleeds,	which	were	calculated	to	account	for	21%	of	the	association	between	AD	mutation	status	and	WMH.	In	later	AD,	it	is	likely	that	the	decline	in	perfusion	continues	to	exceed	the	reduction	in	metabolic	demand	but	less	so	than	in	early	disease.	Several	functional	MRI	studies	have	demonstrated	an	increase	in	the	regional	oxygen	extraction	fraction	(rOEF)	in	the	cerebral	cortex	and	white	matter	in	AD	(83,	84,	137),	indicating	a	continued	pathological	reduction	in	blood	supply.	Indeed,	in	the	series	of	Toghi	et	al	(137),	rOEF	was	higher	in	the	cerebral	cortex	of	patients	
with	AD	than	in	those	with	vascular	dementia	(in	the	white	matter	the	increase	was	more	marked	in	patients	with	vascular	dementia).	Our	own	studies	found	the	MAG:PLP1	ratio	to	be	reduced	in	the	cerebral	cortex	in	late,	as	well	as	early	AD	(75,	134).	However,	within	the	precuneus,	the	ratio	was	not	as	markedly	decreased	in	brain	tissue	from	patients	with	Braak	stage	V-VI	disease	as	in	those	with	earlier	(Braak	stage	III-IV)	disease	and	not	significantly	so	in	comparison	with	Braak	stage	0-II	disease	(Figure	2).	We	interpreted	this	lessening	of	the	perfusion	deficit	as	being	likely	to	reflect	falling	metabolic	demand	with	increasing	synaptic	and	neuronal	damage.		
Mechanisms:	metabolic	vascular	dysfunction	Under	normal	circumstances,	cerebral	perfusion	is	tightly	regulated	to	match	the	supply	of	oxygenated	blood	to	metabolic	requirements,	both	of	the	brain	as	a	whole	(through	autoregulation	–	the	maintenance	of	relatively	constant	blood	flow	despite	changes	in	perfusion	pressure)	and	of	the	individual	regions	within	it	(through	neurovascular	coupling)	(25,	106).	This	regulation	is	effected	through	multiple	neurogenic,	myogenic	and	metabolic	pathways.	In	AD,	the	activity	of	several	pathways	that	regulate	intracerebral	vascular	tone	and	influence	neurovascular	coupling	is	abnormally	altered.	Most	of	the		alterations	promote	vasoconstriction,	acting	on	smooth	muscle	cells	in	the	tunica	media	of	arterioles,	on	pericytes	in	capillaries	or	on	both	types	of	cell,	and	reduce	tissue	oxygenation.	Other	abnormalities	allow	inappropriate	local	vasodilatation,	diverting	blood	away	from	regions	of	higher	metabolic	demand.	Both	types	of	alteration	have	the	potential	to	affect	neurological	function	and,	if	sustained,	to	cause	permanent	damage.	
	
Cerebral	cortex	
Cholinergic	innervation	Arterioles	in	the	cerebral	cortex	are	innervated	by	cholinergic	nerves,	originating	in	the	nucleus	basalis	of	Meynert	(139,	142).	Stimulation	of	neurons	in	the	nucleus	basalis	(see	(26)	for	review)	or	of	muscarinic	receptors	in	isolated	arterioles	(48)	causes	vasodilatation,	partly	mediated	by	stimulation	of	the	production	of	nitric	oxide	(NO)	(151).	Tong	and	Hamel	(139)	found	a	reduction	in	the	cholinergic	innervation	of	cortical	blood	vessels	in	AD,	mirroring	a	general	loss	of	cholinergic	nerve	terminals	from	the	cerebral	cortex	and	in	keeping	with	the	loss	of	neurons	from	the	nucleus	basalis	from	an	early	stage	of	disease	(see	(31,	68)	for	review).	Cholinergic	deafferentation	reduces	blood	flow	in	the	cerebral	cortex,	as	was	demonstrated	after	targeted	ablation	of	cholinergic	neurons	by	administration	of	192	IgG-saporin	(144).	Although	interpretation	of	the	findings	is	complicated	by	possible	effects	of	cholinergic	denervation	on	neuronal	activity	and	metabolic	demand,	it	seems	likely	that	reduced	stimulation	of	muscarinic	receptors	in	the	walls	of	cortical	arterioles	contributes	to	the	hypoperfusion	of	the	cortex	in	AD,	and	possible	beneficial	effects	of	cholinesterase	inhibitors	in	AD	may	relate	partly	to	augmented	cerebral	perfusion	(13,	26).	It	should	be	noted	that	AD	is	also	associated	with	alterations	in	a	range	of	other	neurotransmitters	that	have	direct	or	indirect	effects	on	vascular	contractility,	including	glutamate,	γ-aminobutyric	acid,	noradrenaline	(norepinephrine),	serotonin	and	dopamine	(28,	34,	44,	63,	113).		
	 	
Amyloid-β	peptide	(Aβ)	Perhaps	not	surprisingly,	several	of	the	processes	that	mediate	vascular	dysfunction	in	AD	are	probably	initiated	by	the	accumulation	of	Aβ.	Topical	application	of	Aβ40	or	Aβ42	to	isolated	arteries	causes	vasoconstriction,	Aβ40	being	more	potent	than	Aβ42	in	this	regard	(29).	The	vasoconstriction	can	be	reduced	by	free	radical	scavengers	and	cyclo-oxygenase	inhibitors	(99,	112,	135,	140).	Aβ40	enhances	the	constriction	induced	by	endothelin-1	(EDN1)	and	reduces	the	vasodilatation	produced	by	NO	(99,	101).	Aβ40	also	induces	vasoconstriction	in	vivo,	as	demonstrated	by	its	application	to	mouse	cortex	(89).	This	can	be	prevented	by	administering	free	radical	scavengers	or	by	an	M35Nle	amino	acid	substitution	in	Aβ40	which	interferes	with	its	ability	to	generate	reactive	oxygen	species	(89,	90).	In	a	series	of	studies	on	mice	overexpressing	Aβ-precursor	protein	(APP),	Iadecola	and	colleagues	showed	that	elevated	endogenous	Aβ	also	caused	vasoconstriction	from	an	early	age	(2	months	in	Tg2576	mice,	well	before	plaque	formation),	impaired	autoregulation	and	interfered	with	neurovascular	coupling	(in	this	case	the	functional	hyperaemia	of	the	barrel	cortex	that	is	normally	induced	by	whisker	stimulation)	(86-88,	90).	Shin	et	al	(125)	confirmed	that	Tg2576	mice	had	an	attenuated	hyperaemic	response	to	hypercapnia	and	whisker	stimulation	but	were	unable	to	demonstrate	this	until	the	mice	had	reached	the	age	of	9	months,	i.e.	after	commencement	of	vascular	deposition	of	Aβ.	The	authors	suggested	that	vascular	deposition	of	Aβ	was	a	prerequisite	for	the	vascular	dysfunction.	It	is	also	possible	that	the	development	of	vascular	dysfunction	in	these	mice	simply	depends	on	the	concentration	of	soluble	Aβ,	which	increases	with	age,	although	it	is	not	clear	why	the	two	research	groups	found	so	marked	a	
difference	in	the	timing	of	onset	of	the	dysfunction.	The	abnormal	cerebral	vasoconstriction	in	Tg2576	mice	requires	the	production	of	free	radicals	by	nicotinamide	adenine	dinucleotide	phosphate	oxidase	(NADPH	oxidase),	as	shown	by	studies	in	which	NADPH	oxidase	was	either	inhibited	(103),	or	inactivated	by	deletion	of	Nox2	(104).	These	findings	are	in	keeping	with	the	studies	on	isolated	arteries,	described	above.		For	simplicity,	the	various	processes	that	contribute	to	hypoperfusion	in	AD	are	considered	under	separate	headings	in	the	present	review.	However,	as	noted	below,	the	different	pathways	overlap	and	interact	substantially	–	particularly	insofar	as	they	involve	Aβ,	e.g.	in	upregulating	the	production	of	EDN1	by	endothelin-converting	enzymes-1	and	-2	(ECE1	and	ECE2)	and	that	of	angiotensin	II	(Ang	II)	by	angiotensin-converting	enzyme	(ACE),	in	reducing	NO	production	by	endothelial	cells,	in	binding	to	and	sequestering	vascular	endothelial	growth	factor	(VEGF)	in	plaques,	and	in	blocking	VEGF	receptor	2	(VEGFR-2)	signalling	in	endothelial	cells.	There	is	also	interaction	between	the	endothelin	and	renin-angiotensin	systems	(reviewed	in	(76));	Aβ	and	the	cholinergic	systems	(see	(55,	94,	147)	for	review);	and	the	cholinergic	system	and	VEGF	production	(53).			
Endothelin	system	EDN1	is	a	potent	vasoconstrictor	and	its	concentration	is	increased	significantly	in	cerebral	cortex	from	patients	with	AD	(75,	97,	134).	The	increase	is	demonstrable	from	an	early	stage	of	disease,	including	within	the	precuneus	(75),	the	first	region	in	which	blood	flow	declines	(see	above).	Paradoxically,	the	gene	that	encodes	EDN1	is	also	upregulated	by	hypoxia	(127).	The	extent	to	
which	EDN1	is	increased	in	AD	correlates	with	the	severity	of	cortical	hypoperfusion/tissue	hypoxia,	as	measured	by	the	decline	in	the	MAG:PLP1	ratio.	Both	Aβ40	and	Aβ42	are	capable	of	increasing	EDN1	production	in	vitro:	Aβ40	through	upregulation	of	ECE1	in	endothelial	cells	(97,	98),	and	Aβ42	through	upregulation	of	ECE2	in	neurons	(96).	In	cortex	from	patients	with	AD	the	concentration	of	EDN1	correlates	closely	with	that	of	Aβ42	but	bears	no	relationship	to	that	of	Aβ40	(75),	suggesting	that	the	increase	in	EDN1	and	decrease	in	tissue	oxygenation	are	caused,	at	least	in	part,	by	Aβ42-mediated	neuronal	upregulation	of	ECE2.	Aβ	is	a	physiological	substrate	of	both	ECEs	(36-38)	and	the	upregulation	of	ECE2	and	consequent	sustained	overproduction	of	EDN1	in	AD	may	simply	be	an	unfortunate	side	effect	of	the	parenchymal	accumulation	of	substrate	in	the	form	of	Aβ42	(76).	The	lack	of	association	between	Aβ40	and	EDN1	(or	MAG:PLP1)	does	not	discount	a	role	for	Aβ40	in	the	vascular	dysfunction	of	AD,	but	such	a	role	is	likely	to	be	predominantly	episodic:	interfering	with	autoregulation	and	neurovascular	coupling	rather	than	causing	sustained	hypoperfusion.	Palmer	et	al	(98)	showed	that	the	enhanced	release	of	EDN1	that	follows	the	addition	of	Aβ40	to	human	cerebrovascular	endothelial	cells	in	vitro	could	be	prevented	by	the	addition	of	superoxide	dismutase,	potentially	linking	upregulation	of	ECE1	with	the	observations	of	Niwa	et	al	(89,	90)	on	free-radical	mediated	vasoconstriction,	and	suggesting	that	the	episodic	cerebral	vasoconstriction	induced	by	Aβ40	results	from	a	free	radical-mediated	increase	in	endothelial	ECE-1	activity	and	EDN1	production.		
	 	
Angiotensin	Increased	production	of	the	vasoconstrictor	Ang	II	may	contribute	to	hypoperfusion	of	the	frontal	cortex,	where	ACE	activity	(74,	77,	78)	and	Ang	II	level	(unpublished	observations)	are	elevated	in	AD,	perhaps	in	response	to	the	accumulation	of	Aβ42.	Miners	et	al	(78)	showed	that	ACE	activity	in	SH-SY5Y	neuroblastoma	cells	was	upregulated	by	aggregated	Aβ42	(but	not	Aβ40	or	freshly	solubilised	Aβ42).	The	relationship	between	Aβ42,	ACE	activity,	Ang	II	production	and	hypoperfusion	is,	however,	less	clear-cut	than	that	between	Aβ42,	ECE1	activity,	EDN1	production	and	hypoperfusion,	in	that	neither	ACE	activity	nor	Ang	II	level	was	increased	in	precuneus	from	patients	with	AD	(75).	Like	so	many	of	the	dysregulated	pathways	that	are	the	focus	of	this	review,	the	renin-angiotensin	system	has	a	complex	interrelationship	with	other	vasoregulatory	processes.	ACE	cleaves	(141)	and	probably	thereby	limits	the	duration	of	action	of	the	vasodilator	bradykinin,	the	production	of	which	is	likely	to	be	elevated	in	AD,	as	a	result	of	increased	activity	of	plasma	kallikrein	(4).	Ang	II	was	reported	to	increase	EDN1	production	in	endothelial	(32)	and	vascular	adventitial	fibroblasts	(1),	probably	by	inducing	transcription	of	the	preproendothelin-1	gene	(117)	and	by	a	mechanism	involving	NADPH	oxidase	(2),	thereby	contributing	to	EDN1-mediated	hypoperfusion.	Conversely,	hypoxia	was	shown	to	upregulate	the	expression	and	activation	of	ACE	(62).		
Endothelial	nitric	oxide	synthase	(eNOS)	NO,	a	potent	vasodilator,	is	synthesized	within	the	endothelium	by	eNOS,	the	activity	of	which	plays	an	important	role	in	local	regulation	of	the	cerebral	microcirculation	(151).	eNOS	is	activated	by	a	wide	range	of	stimuli,	including	
acetylcholine	(40),	bradykinin,	oxidative	stress,	shear	stress	and	hypoxia.	Both	Aβ40	and	Aβ42	inhibit	eNOS	activity.	Aβ40	was	reported	to	do	so	through	a	mechanism	that	depends	on	protein	kinase	C	(46),	and	Aβ42	through	interfering	with	Akt/GSK-3β	signalling	and	a	mechanism	involving	interaction	of	eNOS	with	heat	shock	protein	90	(64,	128).	Mice	partially	deficient	in	eNOS	develop	cognitive	impairment	associated	with	a	range	of	neuropathological	abnormalities,	including	cerebral	amyloid	angiopathy	(CAA)	and	disruption	of	the	blood-brain	barrier	(BBB),	largely	confined	to	the	temporoparietal	and	retrosplenial	granular	cortex	and	hippocampus	(129).	Jeynes	and	Provias	(52)	reported	a	significant	negative	correlation	between	the	number	of	eNOS-immunolabelled	capillaries	and	the	density	of	neurofibrillary	tangles	and	Aβ	plaques	in	sections	of	temporal	and	calcarine	cortex	in	AD.		
White	matter	As	noted	above,	most	of	the	studies	on	mechanisms	of	vascular	dysfunction	in	AD	have	used	rodent	models	and	have	focussed	on	cerebral	cortex.	Whilst	several	of	the	local	metabolic	abnormalities	that	contribute	to	hypoperfusion	of	the	cerebral	cortex	may	also	apply	in	the	white	matter,	our	studies	have	highlighted	differences	that	are	relevant	to	our	understanding	of	the	pathogenesis	of	ischaemic	white	matter	damage	in	AD	and	have	implications	for	treatment.	Whereas	we	found	the	concentration	of	EDN1	to	be	elevated	approximately	twofold	in	the	cerebral	cortex	in	AD,	presumably	in	response	to	Aβ42-induced	upregulation	of	ECE2,	EDN1	level	was	significantly	reduced	in	the	underlying	white	matter	(8,	75).	This	reduction	occurred	in	association	with	a	modest	decline	in	MAG	and	in	MAG:PLP1	in	the	white	matter	(9)	(in	keeping	with	other	
evidence	of	ischaemic	white	matter	damage	in	AD,	e.g.	on	neuroimaging,	as	discussed	above).	The	relationship	between	MAG:PLP1	and	EDN1	in	the	white	matter	was	the	converse	of	that	in	the	cortex:	in	the	cortex	MAG:PLP1	and	EDN1	correlated	negatively	and	in	the	white	matter	they	correlated	positively	(75).	White	matter	hypoperfusion	in	AD	is	not	therefore	caused	by	increased	white	matter	EDN1,	which	falls	as	would	be	expected	physiologically	in	response	to	hypoperfusion.	However,	MAG:PLP1	in	the	white	matter	did	correlate	positively	with	the		concentration	of	EDN1	in	the	overlying	cortex,	suggesting	that	hypoperfusion	of	the	white	matter	in	AD	results	partly	from	vasoconstriction	of	perforating	arterioles	as	they	traverse	the	cortex	(Figure	3)	(23,	75).	This	mechanism	of	white	matter	hypoperfusion	is	likely	to	be	relevant	to	other	Aβ-dependent	processes	that	increase	vasoconstriction	within	the	cortex,	including	cholinergic	denervation,	Ang	II	production	and	reduction	in	activity	of	eNOS.		
Mechanisms:	structural	abnormalities	of	the	cerebral	
vasculature	The	abnormalities	described	above	affect	vascular	function	but	are	not	associated	with	long-lasting	structural	alterations.	As	recently	reviewed	(71),	patients	with	AD	also	have	an	increased	prevalence	of	structural	disease	of	cerebral	microvessels,	particularly	CAA	and	capillary	damage.	They	may	also	have	more	severe	non-amyloid	small	vessel	disease	(SVD)	than	elderly	people	without	AD	but	most	of	the	cited	evidence	is	indirect,	based	on	the	identification	of	white	matter	abnormalities	on	neuroimaging,	and	as	likely	to	have	resulted	from	CAA	or	capillary	damage	as	from	SVD.	An	MRI-based	study	of	regional	
cerebrovascular	resistance	(CVRi)	found	this	to	be	increased	in	several	regions	of	brain	that	are	not	affected	by	CAA	and	have	a	predilection	for	SVD,	including	thalamus	and	caudate	nucleus	(85),	but	the	pathological	substrate	of	the	increased	CVRi	remains	to	be	demonstrated.	For	further	consideration	of	the	possible	association	of	SVD	with	AD,	see	(71).		
Cerebral	amyloid	angiopathy	Most	patients	with	AD	have	CAA,	in	some	series	over	90%,	compared	to	about	30%	in	elderly	controls	(21,	42,	69,	72,	73,	143,	146).	In	many	cases	the	CAA	is	relatively	mild,	affecting	only	occasional	arterioles	in	the	leptomeninges,	but	some	patients	have	widespread	involvement	of	cortical	and	meningeal	arterioles,	as	well	as	deposition	of	Aβ	in	the	adventitia	of	meningeal	venules.	In	patients	with	AD,	possession	of	APOE	ϵ4	is	a	risk	factor	for	more-severe	CAA	(21,	111,	121)	and	is	strongly	associated	with	capillary	CAA	(6,	69,	133)	(in	controls,	arteriolar	Aβ	amyloid	angiopathy	is	more	strongly	associated	with	APOE	ϵ2).	In	the	majority	of	patients	CAA	is	restricted	to	the	cerebral	cortex	and	overlying	leptomeninges	but	it	may	also	involve	the	cerebellum	(particularly	the	meningeal	vessels)	and	occasionally	the	brain	stem.	Aβ	may	also	accumulate	in	the	walls	of	capillaries,	sometimes	extensively	so.	Capillary	CAA	predominantly	involves	the	entorhinal	and	occipital	cortex	but	can	be	present	in	other	parts	of	the	neocortex	and	is	often,	but	not	always,	associated	with	severe	arteriolar	CAA.	CAA	has	several	adverse	effects	on	cerebral	perfusion.	Perhaps	the	most	widely	recognised	are	cerebral	micro-haemorrhages	and	larger	lobar	haemorrhages,	but	there	is	also	extensive	documentation	of	ischaemic	abnormalities	(predominantly	cortical	microinfarcts)	(3,	18,	41,	43,	93,	138),	
some	of	which	are	caused	by	local	thrombosis,	some	by	the	marked	narrowing	of	severely	affected	blood	vessels,	and	some	probably	by	impaired	neurovascular	coupling.	Evidence	of	neurovascular	decoupling	in	human	patients	comes	from	MRI	studies	of	occipital	vascular	reactivity	in	response	to	visual	stimulation	in	patients	with	probable	CAA	(35,	107,	126).	Peca	et	al	(107)	also	found	that	impaired	neurovascular	coupling,	as	evidenced	by	lower	functional	MRI	responses	to	visual	stimuli,	was	associated	with	more	microbleeds	and	a	higher	volume	of	white	matter	lesions,	linking	impairment	of	neurovascular	coupling	with	severity	of	tissue	damage.		
Capillary	damage	The	capillary	bed	constitutes	much	the	largest	part	of	the	cerebral	vasculature	and	is	also	the	most	important	in	terms	of	metabolic	homeostasis.	Yet	the	contribution	of	capillary	damage	to	hypoperfusion	in	AD	has	been	somewhat	neglected,	perhaps	because	of	the	small	size	and	inconspicuous	histological	appearance	of	individual	capillaries.	Despite	the		hypoperfusion,	the	density	of	capillaries	in	the	cerebral	cortex	is	unchanged	or	reduced	in	AD	(8,	15,	17,	45,	60,	134),	and	more	of	them	show	degenerative	changes	in	AD	than	in	age-matched	controls	(7,	20,	51,	123).	Both	endothelial	cells	and	pericytes	are	affected,	their	degeneration	eventually	leaving	residual	'string'	vessels	consisting	solely	of	tubes	of	collagen.	These	degenerative	changes	occur	despite	a	significant	increase	in	the	concentration	of	VEGF	in	AD	(54,	75,	130,	134),	which	would	be	expected	to	promote	angiogenesis,	with	the	formation	of	new	capillaries	(92,	150).	Several	factors	may	contribute	to	this	lack	of	angiogenic	response.	Aβ	peptides	have	direct	anti-angiogenic	activity	(99,	100,	
102)	and	also	bind	to	VEGF	receptor	2,	blocking	VEGF	signalling.	In	addition,	Aβ	within	plaques	binds	and	thereby	potentially	sequesters	VEGF,	interfering	with	its	biological	availability	(105,	148).	At	the	level	of	the	capillary	bed,	degeneration	of	pericytes	has	emerged	as	a	key	contributor	to	hypoperfusion.	Changes	in	the	contractile	activity	of	pericytes	modulate	capillary	calibre	and	cerebral	blood	flow	and	probably	play	an	important	role	in	neurovascular	coupling	(10,	49,	108).	Dore-Duffy	et	al	reported	that	pericytes	in	primary	cultures	express	both	EDN1	and	its	two	receptors	(EDNRA	and	EDNRB)	(33).	The	authors	also	provided	in	vivo	evidence	that	EDN1	(which	is	elevated	in	AD	–	see	above)	contributes	to	the	regulation	of	capillary	perfusion	through	binding	to	EDNRA	receptors	in	pericytes.	Experimental	traumatic	brain	injury	in	mice	caused	an	increase	in	the	number	of	smooth	muscle	actin-positive	pericytes	around	capillaries,	a	rise	in	capillary	EDN1,	and	reduced	capillary	diameter.	These	changes	could	be	prevented	by	administration	of	an	EDNRA	antagonist.	Pericytes	are	also	important	for	maintenance	of	the	blood-brain	barrier	(10).	A	series	of	studies	by	Zlokovic	and	colleagues	have	shown	that	loss	of	pericytes	exacerbates	multiple	pathological	processes	in	AD	(145),	including	hypoperfusion	and	disruption	of	the	blood-brain	barrier	(10,	123),	accumulation	of	Aβ40	and	Aβ42,	tau	pathology	and	neuronal	loss	(120).	Montagne	et	al	(80)	quantified	blood-brain	barrier	permeability	in	the	hippocampus	of	young	and	older	adult	volunteers	by	dynamic	contrast-enhanced	MRI,	and	showed	the	degree	of	increase	in	permeability	to	correlate	with	the	CSF:plasma	albumin	ratio	(a	marker	of	blood-brain	barrier	breakdown)	and	the	CSF	concentration	of	soluble	platelet-derived	growth	factor	receptor	β	(a	marker	of	pericyte	injury).	
Both	blood-brain	barrier	permeability	and	pericyte	injury	were	more	pronounced	in	participants	with	MCI	than	in	older	individuals	who	were	cognitively	normal.		
Therapeutic	implications	There	is	therefore	overwhelming	evidence	of	a	wide	range	of	functional	and	structural	abnormalities	of	the	cerebral	microvasculature	in	AD,	that	contribute	to	hypoperfusion	and	the	resulting	energy	deficit	as	well	as	to	other	aspects	of	the	disease.	Implications	for	therapy	are	both	specific	and	general.	Specific	implications	concern	the	potential	for	targeting	of	particular	pathways	or	receptors	to	ameliorate	the	vascular	abnormalities	–	particularly	those	that	are	not	the	result	of	structural	changes.	General	implications	relate	to	the	timing	and	broader	consequences	of	intervention.	Several	of	the	pathways	implicated	in	abnormal	microvascular	function	in	AD	are	potentially	amenable	to	treatment.	The	cholinergic	system	is,	of	course,	already	routinely	targeted	in	AD	patients	through	the	administration	of	cholinesterase	inhibitors.	These	drugs	improve	cerebral	perfusion	in	mild	to	moderate	disease	(19),	and	several	studies	found	evidence	of	an	association	between	cognitive	response	and	cerebral	blood	flow	(13,	26,	124).	The	potential	for	intervention	in	the	renin-angiotensin	system	has	been	extensively	reviewed	(56-59)	and	the	effects	on	cognition	and	cerebral	blood	flow	of	losartan,	an	angiotensin	receptor	antagonist,	are	currently	being	tested	in	a	multicentre	UK	clinical	trial	(115).	Another	potential	target	is	the	endothelin	system.	Bosentan,	a	non-selective	EDNR	antagonist	(119),	improves	pulmonary	blood	flow	and	exercise	
tolerance	in	patients	with	pulmonary	hypertension,	another	disease	in	which	there	is	elevated	production	of	EDN1	(114,	118).	Bosentan	also	preserves	endothelium-dependent	aortic	and	carotid	vasodilatation	in	Tg2576	mice	(39).	Selective	EDNRA	receptor	antagonists	such	as	zibotentan		(50,	81)	offer	theoretical	advantages,	in	that	they	target	the	predominant	type	of	EDN1	receptor	responsible	for	mediating	vasoconstriction	in	both	smooth	muscle	cells	of	cerebral	arterioles	and	pericytes	that	surround	capillaries	(33,	91).	For	discussion	see	(95).	Interventions	aimed	at	reversing	functional	abnormalities	of	the	vasculature	in	AD	have	the	potential	not	only	to	improve	symptoms	but	also	to	slow	the	progression	of	disease.	Hypoperfusion	probably	increases	the	production	of	Aβ42,	thereby	accelerating	the	progression	of	disease.	Simulation	of	neuronal	ischaemia	in	vitro,	or	experimental	cerebral	hypoperfusion	in	animal	models	increases	Aβ42	production	through	multiple	mechanisms	(reviewed	in	(70,	71)),	including	upregulation	of	amyloid-β	precursor	protein	and	β-secretase	and	possibly	reduced	neprilysin-mediated	degradation.	Indirect	evidence	of	a	hypoperfusion-induced	increase	in	Aβ	comes	from	observations	in	patients	who	had	survived	a	recent	cardiac	arrest	(149)	or	diffuse	traumatic	brain	injury	with	cerebral	oedema	(and	therefore	almost	certainly	hypoperfusion)	(79).	Both	groups	had	elevated	serum	Aβ42	over	several	days.	In	the	patients	with	diffuse	traumatic	brain	injury,	Aβ42	was	also	monitored	in	the	CSF	where	the	level	declined,	arguing	against	non-specific	leakage	of	Aβ	from	damaged	brain	tissue	as	the	explanation	for	the	rising	level	in	the	serum.	The	timing	of	intervention	is	likely	to	be	critical,	as	prolonged	hypoperfusion	causes	permanent	brain	damage	(as	discussed	above),	and	as	the	
disease	progresses	the	balance	tends	to	shift	from	metabolic	to	structural	vascular	dysfunction	(Figure	4).	It	seems	possible	too	that	prolonged	cerebral	hypoperfusion	may	induce	compensatory	changes	in	the	circulation	that	are	themselves	damaging,	including	hypertension	and	SVD.	Mid-life	hypertension	is	significantly	associated	with	AD	(109,	110)	Several	clinical	studies	have	reported	an	association	between	hypertension	before	the	age	of	65	years	(particularly	if	there	is	elevation	of	diastolic	blood	pressure)	and	later	development	of	AD	(61,	66,	82).	Hypertension	in	cognitively	normal	adults	with	at	least	1	APOE	ϵ4	allele	was	associated	with	increased	binding	of	the	Aβ	tracer	F18–labelled	florbetapir	(116).	The	conventional	interpretation	is	that	hypertension	increases	the	risk	of	developing	AD	by	promoting	the	accumulation	of	Aβ.	However,	another	possible	explanation	is	that	hypertension	is	a	physiological	response	to	tonic	cerebral	vasoconstriction	induced	by	mid-life	accumulation	of	Aβ;	a	means	of	maintaining	cerebral	perfusion.	There	is	experimental	evidence	that	this	is	the	case,	in	that	cerebroventricular	infusion	of	Aβ	was	shown	to	cause	a	progressive,	highly	significant	rise	in	blood	pressure	in	rats	(132).	This	has	obvious	implications	for	autoregulation	and	for	the	treatment	of	hypertension	once	Aβ	has	begun	to	accumulate,	and	suggests	that	blood	pressure	in	such	patients	should	be	lowered	only	cautiously,	ideally	with	monitoring	of	the	effects	on	cerebral	perfusion.		
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Figure	1.	Schematic	illustration	of	the	distribution	of	MAG	(pink	dots)	and	PLP1	(green	dots)	in	the	myelin	sheath.	PLP1	is	distributed	throughout	the	myelin	sheath	whereas	MAG	is	inserted	only	far	from	the	cell	body,	in	the	adaxonal	loop	of	myelin,	the	first	part	of	the	sheath	to	degenerate	when	blood	supply	is	insufficient	to	meet	the	energy	demands	of	the	oligodendrocyte.	As	MAG	and	PLP1	are	stable	post	mortem	and	have	half-lives	of	several	months,	a	decline	in	MAG:PLP1	in	post-mortem	brain	tissue	reflects	a	hypoperfusion-related	energy	deficit		over	a	relatively	long	period	prior	to	death.		Image	adapted	from	(71).		
	
Figure	2.	Bar	chart	showing	decline	of	MAG:PLP1	in	the	precuneus	in	AD.	The	decline	is	most	marked	in	early	disease	(Braak	tangles	stage	III-IV).	The	ratio	may	rise	in	late	disease	as	a	consequence	of	falling	metabolic	demand.	Reproduced	from	(75).		
	
Figure	3.	Perforating	arterioles	that	arise	from	meningeal	branches	of	the	major	cerebral	arteries	supply	both	the	cerebral	cortex	and	the	underlying	white	matter.	Excessive	vasoconstriction	within	the	cerebral	cortex	in	AD	affects	not	only	cortical	arterioles	but	also	perforating	arterioles	that	traverse	the	cortex.	Thus	vasoconstriction	within	the	cerebral	cortex	contributes	to	hypoperfusion	of	the	white	matter	even	if	arterioles	in	the	white	matter	are	not	themselves	constricted.	Modified	from	(23).		
	
Figure	4.	Shift	from	purely	metabolic	to	structural	vascular	dysfunction	over	the	course	of	AD	(in	relation	to	the	onset	of	clinical	disease,	at	0	years).	After	a	brief	period	of	increased	metabolic	demand	and	cerebral	blood	flow,	the	progressive	accumulation	of	Aβ	in	early	(preclinical)	stages	of	AD	drives	several	metabolic	pathways	that	lead	to	excessive	vasoconstriction	and	reduced	cerebral	perfusion.	Cerebral	perfusion	declines	faster	than	metabolic	demand.	Aβ42-induced	metabolic	processes	may	be	more	important	in	driving	chronic	hypoperfusion,	and	Aβ40-induced	processes	in	impairing	vascular	responsiveness.	As	the	disease	progresses,	capillary	damage	and,	in	many	patients,	CAA,	become	increasingly	important	contributors	to	both	chronic	hypoperfusion	and	abnormalities	of	autoregulation	and	neurovascular	coupling.			
